



(12) Translation of
European patent specification

(11) NO/EP 2914264 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/506 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2018.01.29
(80)	Date of The European Patent Office Publication of the Granted Patent	2017.08.09
(86)	European Application Nr.	13776720.8
(86)	European Filing Date	2013.10.04
(87)	The European Application's Publication Date	2015.09.09
(30)	Priority	2012.11.02, EP, 12007494
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Merck Patent GmbH, Frankfurter Strasse 250, 64293 Darmstadt, DE-Tyskland
(72)	Inventor	FRIESE-HAMIM, Manja, Stockhausenstrasse 1, 64546 Moerfelden-Walldorf, DE- Tyskland BLADT, Friedhelm, Werderstrasse 36, 69120 Heidelberg, DE-Tyskland
(74)	Agent or Attorney	Tandberg Innovation AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	A 6-OXO-1,6-DIHYDRO-PYRIDAZINE DERIVATIVE FOR THE USE FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
(56)	References Cited:	WO-A1-2010/078897

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

- 5 **1.** 3-(1-{3-[5-(1-metyl-piperidin-4-ylmetoksy)-pyrimidin-2-yl]-benzyl}-6-okso-1,6-dihydro-pyridazin-3-yl)-benzonitril eller et farmasøytisk akseptabelt salt og/eller solvat derav for anvendelse ved behandling av hepatocellulært karsinom (HCC).
- 10 **2.** 3-(1-{3-[5-(1-metyl-piperidin-4-ylmetoksy)-pyrimidin-2-yl]-benzyl}-6-okso-1,6-dihydro-pyridazin-3-yl)-benzonitrilhydrokloridhydrat for anvendelse ved behandling av hepatocellulært karsinom (HCC).
- 15 **3.** 3-(1-{3-[5-(1-metyl-piperidin-4-ylmetoksy)-pyrimidin-2-yl]-benzyl}-6-okso-1,6-dihydro-pyridazin-3-yl)-benzonitril ifølge krav 1 eller 2, hvor forbindelsen administreres til en pasient i en mengde på 100 mg til 800 mg per dag.
- 4.** 3-(1-{3-[5-(1-metyl-piperidin-4-ylmetoksy)-pyrimidin-2-yl]-benzyl}-6-okso-1,6-dihydro-pyridazin-3-yl)-benzonitril ifølge krav 1, 2 eller 3, hvor forbindelsen administreres oralt.